We're a Baker Tilly network member
Learn more
Federal Budget 2022-23: Patent box measures
Article

Federal Budget 2022-23: Patent box measures

The Government has announced that it will be expanding the patent box measures announced in last year’s Budget to additional sectors to drive more investment and encourage Australian companies to commercialise their innovations in Australia.

Expanding the patent box tax concession to Australian agricultural and low emission technology sectors

The Government has announced that it will be expanding the patent box measures to support additional sectors, including the Australian agricultural sector and low emission technology sector.

From 1 July 2023, it is proposed that eligible corporate income will be subject to an effective income tax rate of 17 percent for patents granted or issued after 29 March 2022. Eligible income will be concessionally taxed to the extent that the research and development (“R&D”) activities relating to the innovation took place in Australia.

The Government will consult with industry prior to finalising the detailed design of the patent box expansion to the additional sectors.

It is anticipated that the patent box measures will offer a competitive tax rate for profits generated from eligible Australian owned and developed patents, which will ultimately support the commercialisation of innovation and encourage further R&D activities in Australia.

Updated policy specifications for Australian medical and biotechnology innovations

In last year’s Budget, the Government announced that it would look to introduce patent box measures where income earned from new medical and biotechnology patents developed in Australia would be taxed at a concessional rate of 17 per cent. These measures are currently before Parliament and are expected to apply to companies for income years commencing on or after 1 July 2022.

In this year’s Budget, the Government has announced that it would be expanding the policy specifications relating to the Australian medical and biotechnology sector, by enabling patents granted or issued after 11 May 2021 to be eligible for the regime. Further, the Government has removed certain regulatory barriers around the registration of Australian developed innovations patented overseas.

Whilst the patent box measures have been expanded for the medical and biotechnology sector, it remains that taxpayers can only benefit from this regime to the extent that the R&D activities relating to the development of the patent occurred in Australia.

Return to Federal Budget hub

This content is general commentary only and does not constitute advice. Before making any decision or taking any action in relation to the content, you should consult your professional advisor. To the maximum extent permitted by law, neither Pitcher Partners or its affiliated entities, nor any of our employees will be liable for any loss, damage, liability or claim whatsoever suffered or incurred arising directly or indirectly out of the use or reliance on the material contained in this content. Pitcher Partners is an association of independent firms. Pitcher Partners is a member of the global network of Baker Tilly International Limited, the members of which are separate and independent legal entities. Liability limited by a scheme approved under professional standards legislation.

Our experts

Ben Brazier

Ben Brazier

Managing Principal Adelaide
Nigel Fischer

Nigel Fischer

Managing Partner Brisbane
Brendan Britten

Brendan Britten

Managing Partner Melbourne
Michael Minter

Michael Minter

Managing Partner Newcastle and Hunter
Leon Mok

Leon Mok

Managing Director Perth
Adam Irwin

Adam Irwin

Managing Partner Sydney
Pitcher Partners insights Get the latest Pitcher Partners updates direct to your inbox

Thank you for you interest

How can we help you?

Business or personal advice
General information
Career information
Media enquiries
Contact expert
Become a member
Specialist query
Please provide as much detail to ensure appropriate allocation of your query
Please highlight a realistic time frame that will enable us to provide advice within a suitable and timely manner. Please note given conflicting demands with our senior personnel, we will endeavour to respond to you within the nominated time frame. If you require an urgent response, please contact us via [email protected] or 03 8610 5477.
CPN Enquiry
Business Radar report
Student careers 2021-22
Find an expert
Search by industry